Loading…
Loading…
MANE (Veradermics, Incorporated) is a recent IPO.
It began trading on February 4, 2026, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi's 2026 Biopharma Back to School Conference Presentation: Wednesd.
Bamco Inc. NY increased its position in shares of Veradermics, Incorporated (NYSE: MANE) by 284.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 229,581 shares of the company's stock after acquiring an additional 169,913 shares during the period. Bamco Inc. NY owned
Veradermics, Incorporated (NYSE: MANE - Get Free Report) Director John Childs sold 100,000 shares of Veradermics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the sale, the director directly owned 194,117 shares in the company, valued at $20,793,813.04. This
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the p.
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.
Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market opened on Wednesday after Citigroup raised their price target on the stock from $135.00 to $160.00. The stock had previously closed at $110.17, but opened at $118.75. Citigroup currently has a buy rating on the stock. Veradermics shares last traded at
No recent filings indexed.